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Objectives. This study sought to examine effect of vitamin C, an
antioxidant, on the abnormal vasomotor reactivity in spasm
coronary arteries.
Background. Oxygen free radicals generated in the arterial
walls have been shown to cause endothelial vasomotor dysfunc-
tion.
Methods. Responses of the epicardial arterial diameters of the
left coronary arteries to the intracoronary infusion of acetylcho-
line (ACh) (10 and 50 mg/min) were measured by quantitative
coronary angiography before and during combined intracoronary
infusion of vitamin C (10 mg/min) or saline as a placebo in 32
patients with coronary spastic angina and in 34 control subjects.
Results. Vitamin C infusion suppressed the constrictor re-
sponse of the epicardial diameter to ACh in spasm coronary
arteries but had no significant effect in the control coronary
arteries (percent change in distal diameter in response to 10
mg/min of ACh [constriction (2), dilation (1), mean 6 SEM]
before vitamin C: 28.2 6 2.9% in spasm arteries, 18.4 6 2.9%* in
control arteries; during vitamin C: 10.2 6 3.8%* in spasm
arteries, 17.2 6 1.3%* in control arteries [*p < 0.01 vs. spasm
arteries before vitamin C]). The coronary sinus–arterial differ-
ence in plasma thiobarbituric acid reactive substances during
ACh infusion, an indicator of lipid peroxidation in coronary
circulation, was higher in patients with coronary spastic angina
than in control subjects (p < 0.01) but was suppressed in patients
with coronary spastic angina to comparable levels in control
subjects by combined infusion of vitamin C. Saline infusion had
no effect.
Conclusions. The results indicate that vitamin C attenuates
vasomotor dysfunction in epicardial coronary arteries in patients
with coronary spastic angina. Oxygen free radicals may at least in
part play a role in the abnormal coronary vasomotor reactivity in
response to ACh in spasm coronary arteries.
(J Am Coll Cardiol 1998;32:103–9)
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We recently showed (1,2) that the impairment of endothelium-
dependent vasodilation as well as the hypercontractile re-
sponse of smooth muscle in coronary arteries may play an
important role in the genesis of coronary spasm (1,2). It has
been recently shown (3–5) that reactive oxygen molecules
generated in arterial walls and in circulating blood cells might
cause endothelial dysfunction and modify the arterial tone.
Enhanced production of superoxide anions in vascular cells has
been shown (5,6) to inactivate endothelium-derived nitric
oxide, leading to impairment of endothelium-dependent vaso-
dilator response in atherosclerotic arteries. Recent clinical
studies from our and other laboratories (7–10) showed that
supplementation of vitamin C, an antioxidant, restored the
impairment of endothelium-dependent vasodilation in ciga-
rette smokers and in patients with coronary artery disease in
whom oxidative stress is suggested to be increased (11,12).
Therefore, we hypothesized that oxygen-derived free radicals
may cause endothelial dysfunction or inactivate endothelium-
derived nitric oxide, leading also to the abnormal vasomotor
reactivity in spasm coronary arteries of patients with coronary
spastic angina. To test this hypothesis, we examined the effects
of intracoronary infusion of vitamin C on the coronary vaso-
motor reactivity in patients with coronary spastic angina com-
pared with those in control subjects.
Methods
Study subjects. Patients. The study included 32 consecu-
tive patients with coronary spastic angina (mean age 60 years,
range 42 to 75; 18 men, 14 women). The patients with coronary
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spastic angina fulfilled all the following inclusion criteria: 1)
spontaneous attacks of chest pain associated with ST segment
elevation or depression on the 12-lead electrocardiogram
(ECG) or ambulatory ECG at rest, usually in the middle of the
night or early morning; 2) coronary artery spasm (total or
subtotal occlusion) in the left coronary arteries, demonstrated
angiographically during the anginal attack of chest pain with
the ST segment changes during the intracoronary infusion of
acetylcholine (ACh), as previously reported (1,13–15); 3) no
angiographic organic stenosis (,10% stenosis) in coronary
arteries.
Control group. The study also included 34 consecutive
control patients with atypical chest pain (mean age 58 years,
range from 41 to 78; 18 men, 16 women) who were selected to
match the risk factors for coronary artery disease with those in
patients with coronary spastic angina. Control patients under-
went diagnostic cardiac catheterization for evaluation of atyp-
ical chest pain and fulfilled all the following inclusion criteria:
1) no significant ST segment changes during the chest pain on
the 12-lead ECG and ambulatory ECG; 2) no chest pain or ST
segment changes during the treadmill test; 3) angiographically
normal coronary arteries (,10% stenosis) and no coronary
spasm (,50% decrease in coronary diameter from baseline
measurements) during intracoronary infusion of ACh (1,13–
15).
The clinical characteristics of the study patients are shown
in Table 1. All medications except sublingual nitroglycerin
were withdrawn at least 3 days before the study. No study
patient had pharmacologic doses of antioxidants at least 1
month before the study. No study patient had taken nitroglyc-
erin within 6 h of the study. No patient had a previous
myocardial infarction, congestive heart failure, cardiomyopa-
thy, valvular heart disease or other serious disease. Written
informed consent was obtained from all patients before the
study. The study was approved by the ethics committee of our
institution.
Study protocol. The study protocol is shown schematically
in Figure 1. Coronary angiographic study was performed with
the Judkins technique using contrast material (Iopromide,
Schering AG) in the morning, when the patients were fasting.
After baseline measurements of systemic hemodynamic vari-
ables, angiography of the left and right coronary arteries was
performed. Incremental doses of ACh were then infused into
the left anterior descending (LAD) and left circumflex (LCx)
coronary arteries (10, 50, 100 mg/min) and subsequently into
the right coronary artery (RCA) (20 and 50 mg/min) until
coronary spasm was induced or the maximal doses were
reached in all patients of both groups. The infusion of ACh at
the dose of 10 mg/min into the left coronary arteries was
performed for 2 min, and other doses were infused for 1 min
with a 5-min interval between consecutive doses. Measurement
of systemic hemodynamic variables and angiography of the
LAD and LCx were repeated at the end of each infusion.
Coronary spasm induced by this method resolved spontane-
ously within 2 to 3 min without use of nitroglycerin and allowed
further studies in all patients with coronary spastic angina.
Fifteen minutes after the completion of the intracoronary
infusion of ACh, measurement of systemic hemodynamic
variables and control angiography of the left coronary arteries
were performed. Vitamin C (10 mg/min at a rate of 2 ml/min
for 5 min) was then infused into the LAD and LCx through the
Judkins catheter in 20 patients with coronary spastic angina
and in 23 control patients. In the other 12 patients with
coronary spastic angina and in the other 11 control patients,
saline (0.9%) as a placebo of vitamin C was infused (at a rate
of 2 ml/min for 5 min) into the LAD and LCx in the same
manner as vitamin C. This dose of vitamin C yielded 708 6 48
mmol/liter of vitamin C plasma concentration in the coronary
sinus (determined by high performance liquid chromatogra-
phy), levels of which have been reported to be effective as an
antioxidant and have little prooxidant effect (16,17). Measure-
Abbreviations and Acronyms
ACh 5 acetylcholine
ANOVA5 analysis of variance
ECG 5 electrocardiogram
LAD 5 left anterior descending coronary artery (arteries)
LCx 5 left circumflex coronary artery (arteries)
MDA 5 malondialdehyde
RCA 5 right coronary artery (arteries)
TBARS 5 thiobarbituric acid reactive substances





Age (yr) 60 6 10 58 6 9
Men/women 14/18 16/18
Total serum cholesterol (mg/dl) 183 6 33 191 6 28
LDL cholesterol (mg/dl) 109 6 29 117 6 23
HDL cholesterol (mg/dl) 49 6 16 49 6 12
Serum TGs (mg/dl) 123 6 62 124 6 64
Current smoker† 12 (38%) 12 (35%)
Hypertension‡ 9 (28%) 10 (29%)
Diabetes mellitus§ 7 (22%) 6 (18%)
*p 5 NS for all comparisons. †$10 cigarettes/day for 10 years. ‡Blood
pressure $140/90 mm Hg or antihypertensive medication. §Fasting blood
glucose $140 mg/dl or antidiabetic medication. Data presented are mean
value 6 SD or number (%) of patients. CSA 5 coronary spastic angina; HDL 5
high density lipoprotein; LDL 5 low density lipoprotein; TGs 5 triglycerides.
Figure 1. Schematic representation of infusion protocol. Control 5
control patients; CSA 5 patients with coronary spastic angina.
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ments of systemic hemodynamic variables and coronary an-
giography were performed before and at the end of the
infusion. Subsequently, the infusion of vitamin C or saline was
continued for an additional 10 min, and incremental doses of
ACh (10 and 50 mg/min) were simultaneously infused into the
LAD and LCx in exactly the same manner as performed before
the infusion of vitamin C or saline. Measurements of systemic
hemodynamic variables and coronary angiography were re-
peated at the end of the combined infusion of each dose of
ACh with vitamin C or saline. ACh infusion at the dose of
50 mg was not repeated in patients with coronary spastic angina
who had coronary spasm during the ACh infusion at the dose
of 50 mg before the infusion of vitamin C or saline. After an
additional 10 min, intravenous injection of nitroglycerin
(250 mg) was performed, and 2 min thereafter coronary
angiography was performed in multiple projections in all study
patients. All drugs were dissolved in 0.9% saline in a sterile
manner and kept at 37°C. Vitamin C (ascorbic acid) was
purchased from Takeda Pharmaceutical Company (Tokyo,
Japan).
Quantitative coronary angiography. Quantitative coronary
angiographic studies were performed as described in our
previous reports (1,14,15). In the control patients, each trunk
of the LAD and LCx was divided into proximal and distal
segments of equal lengths. The lumen diameter at the center of
each segment was measured to analyze the effects of various
drugs on the epicardial coronary diameter by means of the
computer-assisted coronary angiographic analysis system (Car-
dio 500, Kontron Instruments). In patients with coronary
spastic angina, the lumen diameter was measured at the site of
coronary spasm induced by intracoronary injection of ACh
(1,14). Coronary spasm was defined as total or subtotal occlu-
sion of the epicardial coronary arteries associated with signs of
myocardial ischemia, such as chest pain and ischemic ST
segment changes. When subtotal occlusion occurred diffusely
from the proximal to the distal segments of a coronary artery,
the diameters were measured at both the proximal and distal
segments of the spasm artery. The responses of the coronary
diameter to various drugs were expressed as the percent
change from baseline values on the angiogram taken just
before each infusion of the drugs.
Assays of plasma thiobarbituric acid reactive substances.
A 6F Goodale-Lubin catheter (USCI) for blood sampling was
positioned in the coronary sinus through the right antecubital
vein. EDTA plasma was obtained from the blood in the
coronary sinus and the aortic root at baseline and during each
infusion of various drugs. The lipid peroxidation product in
plasma samples, into which butylated hydroxytoluene at a final
concentration of 20 mmol/liter was added, was measured in
terms of thiobarbituric acid reactive substances (TBARS) (18).
TBARS is expressed using malondialdehyde (MDA) equiva-
lents as a standard.
Statistical analysis. Results are expressed as mean value 6
SEM, unless otherwise indicated. For comparison of coronary
lumenal diameters, systemic hemodynamic variables and
TBARS levels during each infusion of the various drugs
between patients with coronary spastic angina and control
patients, two-way analysis of variance (ANOVA) for repeated
measures, followed by the Bonferroni multiple comparison
test, was used. Serial responses of systemic hemodynamic
variables and TBARS levels in each study group to the
intracoronary infusion of various drugs were compared using
one-way ANOVA. Differences between two means were com-
pared by paired or unpaired Student t test. The correlation
between two continuous variables was examined using linear
regression analysis. Difference in frequencies of risk factors
between patients with coronary spastic angina and control
patients was compared using the chi-square test. A p value
,0.05 was considered statistically significant.
Results
Provocation of coronary spasm. In all patients with coro-
nary spastic angina, spasm occurred in the coronary arteries
into which ACh was infused, in association with both chest pain
and ischemic ST segment changes. Coronary spasm was doc-
umented in 62 coronary arteries (31 LAD, 14 LCx and 17
RCA). Total occlusion occurred at the proximal segment in 10
coronary arteries and at the distal segment in 7, and subtotal
occlusion occurred diffusely in either the proximal or the distal
segments in the remaining 45 coronary arteries. Spasm was
induced by ACh infusion at the dose of 20 mg in 5 coronary
arteries (5 RCA), at 50 mg in 17 arteries (3 LAD, 2 LCx, 12
RCA) and at 100 mg in 40 arteries (28 LAD, 12 LCx). In
contrast, intracoronary infusion of ACh did not induce coro-
nary spasm associated with signs of myocardial ischemia in any
control patient.
Responses of epicardial coronary arteries to ACh. As
shown in Table 2, baseline values of heart rates and mean
blood pressure in patients with coronary spastic angina were
not significantly different from those in control patients. In
patients with coronary spastic angina, the coronary diameter
responses to the infusion of ACh alone and in combination
with vitamin C or saline were analyzed in the LAD and LCx
with the ACh-induced spasm, and this analysis was performed
at the subthreshold concentrations of ACh that did not pro-
voke spasm in the respective coronary arteries with spasm (i.e.,
31 LAD and 14 LCx at 10 mg of ACh; 28 LAD and 12 LCx at
50 mg of ACh) because the diameter of the coronary arteries
during total or subtotal occlusion due to coronary spasm
cannot be accurately measured. In control patients, the diam-
eter responses of 34 LAD and 34 LCx to ACh at 10 and 50 mg
were analyzed as referenced control coronary arteries. Most of
the spasm coronary arteries showed a constrictor response to
the concentrations of 10 and 50 mg of ACh, whereas the
control coronary arteries as a whole showed a slightly dilator
response to both 10 and 50 mg of ACh, as shown in Figure 2.
In the subgroup analysis of the patients with lifelong nonsmok-
ing and no passive smoking, most of the spasm coronary
arteries also showed a constrictor response to ACh infusion,
whereas the control coronary arteries showed a dilator re-
sponse (see later). There were no significant changes in
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systemic hemodynamic variables from baseline values during
infusion of ACh into the LAD and LCx in both patients
groups, as shown in Table 2.
Responses to vitamin C alone and in combination with
ACh. The effects of vitamin C infusion on the coronary lumen
diameters were analyzed in all coronary segments with spasm
in 20 patients with coronary spastic angina (i.e., 40 spasm sites
in 17 proximal [11 LAD, 6 LCx] and 23 distal segments [15
LAD, 8 LCx] of the 31 spasm arteries). The analysis was also
performed at 46 proximal (23 LAD, 23 LCx) and 46 distal
segments (23 LAD, 23 LCx) of the 46 control arteries in 23
control patients.
The epicardial coronary diameters were not significantly
changed after the infusion of vitamin C alone in both spasm
and control coronary arteries (diameters at proximal segment
of spasm arteries [n 5 17]: 2.3 6 0.2 mm before vitamin C vs.
2.3 6 0.1 mm after vitamin C, p 5 NS; diameters at proximal
segments of control arteries [n 5 46]: 2.7 6 0.2 mm before
vitamin C vs. 2.7 6 0.1 mm after vitamin C, p 5 NS). However,
the constrictor response to ACh in spasm coronary arteries was
significantly attenuated by the combined infusion of vitamin C,
whereas the response to ACh in control coronary arteries was
not affected by vitamin C, as shown in Figures 3 and 4. In the
subgroup analysis of the nonsmokers, vitamin C infusion
significantly converted the constrictor response to ACh to the
dilator response in the spasm arteries but had no effect on the
response to ACh in control arteries (percent change in distal
segment from baseline [constriction (2), dilation (1)] in
spasm arteries [n 5 12]: 27.7 6 3.6% during 10 mg of ACh
alone vs. 16.5 6 4.7% during vitamin C plus 10 mg of ACh,
p 5 0.01; in control arteries [n 5 26]: 19.9 6 3.2%* during
10 mg of ACh alone vs. 17.5 6 1.8% during vitamin C plus
10 mg of ACh, p 5 NS [*p 5 0.0001 vs. spasm arteries during
10 mg of ACh alone]). Vitamin C infusion did not significantly
affect systemic hemodynamic variables, as shown in Table 2.
Responses to combined infusion of saline with ACh. Ef-
fects of the saline infusion on the response of the coronary
lumen diameters to ACh infusion were analyzed in all distal
coronary segments with spasm in 12 patients with coronary
spastic angina (i.e., 13 spasm sites at distal segments [12 LAD,
1 LCx]. The analysis was also performed at 22 distal segments
(11 LAD, 11 LCx) of the 22 control arteries in 11 control
patients. Intracoronary infusion of saline did not affect the
response of the epicardial coronary diameters to ACh in both
spasm and control coronary arteries (percent change of distal
segment from baseline in spasm arteries [n 5 13]: 216.6 6
4.7% during 50 mg of ACh alone vs. 218.1 6 5.7% during
saline plus 50 mg of ACh, p 5 NS; in control arteries [n 5 22]:
12.8 6 0.8% during 50 mg of ACh alone vs. 12.3 6 0.7%
during saline plus 50 mg of ACh, p 5 NS). Saline infusion did
not significantly affect systemic hemodynamic variables (data
not shown).
Figure 3. Percent changes in coronary lumen diameter of spasm
arteries from baseline values at proximal (left) and distal segments
(right) in response to ACh with (open circles) or without vitamin C
(solid circles) in patients with coronary spastic angina.











ACh 50 mg NTG
HR (beats/min)
CSA 68 6 15 67 6 13 64 6 12 65 6 13 63 6 10 66 6 12 70 6 13
Control 71 6 10 72 6 12 70 6 10 71 6 11 71 6 7 70 6 9 76 6 13
MBP (mm Hg)
CSA 98 6 13 95 6 13 94 6 14 96 6 11 94 6 12 89 6 15 84 6 12*
Control 100 6 7 95 6 11 95 6 14 96 6 13 96 6 9 95 6 10 89 6 11*
*p , 0.01 versus baseline value. Data presented are mean value 6 SD. ACh 5 acetylcholine; CSA 5 coronary spastic
angina; HR 5 heart rate; MBP 5 mean blood pressure; NTG 5 nitroglycerin.
Figure 2. Percent change in coronary lumen diameter of spasm and
control arteries from baseline values at proximal (left) and distal
segments (right) in response to ACh.
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Baseline coronary diameter and response to nitroglycerin.
Baseline diameters of the spasm arteries in patients with
coronary spastic angina were significantly smaller than those of
the control arteries in control patients (2.4 6 0.2 mm [n 5 13]
vs. 2.7 6 0.1 mm [n 5 34], p , 0.05 at the proximal segment;
1.4 6 0.1 mm [n 5 27] vs. 1.6 6 0.1 mm [n 5 34], p , 0.05 at
the distal segment, respectively, of the LAD). The percent
increase in the coronary diameter after nitroglycerin was
significantly greater in the spasm arteries than in the control
arteries at both the proximal and distal segments (percent
increase from baseline values: 33 6 3% in spasm arteries [n 5
21] vs. 24 6 2% in control arteries [n 5 68] at the proximal
segment, p , 0.05; 31 6 2% in spasm arteries [n 5 36] vs. 22 6
2% in control arteries [n 5 68] at the distal segment, p , 0.05).
The dilator response of the epicardial diameter to nitroglycerin
after the vitamin C infusion was not significantly different from
that after the saline infusion in both spasm and control
coronary arteries (percent dilation of the distal segment from
the baseline: 30 6 2% after vitamin C [n 5 23] vs. 32 6 3%
after saline infusion [n 5 13] in spasm arteries, p 5 NS; 23 6
2% after vitamin C [n 5 46] vs. 20 6 3% after saline infusion
[n 5 22] in control arteries, p 5 NS). Coronary diameters of
the spasm arteries after nitroglycerin administration were not
different from those of the control arteries at either the
proximal or the distal segment (3.2 6 0.1 mm [n 5 13] vs. 3.2 6
0.1 mm [n 5 34] at the proximal segment; 1.8 6 0.1 mm [n 5
27] vs. 1.9 6 0.1 mm [n 5 34] at the distal segment, p 5 NS,
respectively, of the LAD). Thus, the basal tone of the epicar-
dial coronary arteries was increased in the spasm arteries
compared with that in the control arteries. The difference
between the coronary diameter responses to the infusion of
ACh alone and ACh plus vitamin C, reflecting the magnitude
of the vitamin C-induced improvement of vasomotor reactivity
to ACh, was not significantly correlated with the basal coronary
diameter, dilator response to nitroglycerin and constrictor
response to ACh in spasm coronary arteries (difference be-
tween the responses of distal segments to 50 mg of ACh alone
and 50 mg of ACh plus vitamin C [n 5 23]: r 5 20.09 vs. the
basal diameter, p 5 NS; r 5 0.28 vs. the dilator response to
nitroglycerin, p 5 NS; r 5 0.09 vs. the constrictor response to
50 mg of ACh alone, p 5 NS).
TBARS levels in coronary circulation. There was no sig-
nificant difference in TBARS plasma levels (nmol MDA/ml) in
the aortic root at baseline and during each infusion between
patients with coronary spastic angina and control patients
(data not shown). The difference in TBARS levels between the
coronary sinus and the aortic root (calculated by TBARS
plasma level in the coronary sinus minus that in the aortic
root), reflecting the generation of lipid peroxidation in the
coronary circulation, was comparable at baseline between
patients with coronary spastic angina and control patients, as
shown in Figure 5. It was significantly increased from baseline
values during ACh infusion in both patient groups, but the
magnitude of the increase was greater in patients with coro-
nary spastic angina than in control patients during infusion of
ACh, even at the lower concentration that did not provoke
coronary spasm. The coronary sinus–arterial difference of
TBARS levels was further increased during myocardial isch-
emia due to coronary spasm provoked by the higher concen-
trations of ACh in patients with coronary spastic angina (0.6 6
0.4 nmol MDA/ml at baseline; 3.2 6 0.4* during infusion of
50 mg of ACh but without myocardial ischemia; 5.9 6 0.6**
during the myocardial ischemia; *p 5 0.001 vs. baseline; **p ,
0.001 vs. 50 mg of ACh). The coronary sinus–arterial difference
of TBARS levels was not significantly changed from baseline
by the infusion of vitamin C alone in both groups. However,
the combined infusion of vitamin C significantly suppressed the
increase in the coronary sinus–arterial difference of TBARS
levels during ACh infusion in both patient groups to compa-
rable values (Fig. 5), whereas the combined infusion of saline
with ACh had no effect in both groups (patients with coronary
spastic angina [n 5 12]: 3.2 6 0.5 nmol MDA/ml during 50 mg
of ACh alone vs. 2.9 6 0.5 nmol MDA/ml during saline plus
Figure 4. Percent changes in coronary lumen diameter of control
arteries from baseline values at proximal (left) and distal segments
(right) in response to ACh with (open circles) or without vitamin C
(solid circles) in control patients.
Figure 5. Coronary sinus–arterial difference in TBARS at baseline,
during infusion of 50 mg of ACh alone and during infusion of vitamin
C plus 50 mg of ACh in patients with coronary spastic angina (CSA,
n 5 17) and in control patients (Control, n 5 23). Data from patients
with coronary spastic angina in whom spasm in the LAD and LCx was
provoked by infusion of 100 mg, but not 50 mg, of ACh were included
in the analysis.
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50 mg of ACh, p 5 NS; control patients [n 5 11]: 1.8 6 0.3
nmol MDA/ml during 50 mg of ACh alone vs. 1.9 6 0.3 nmol
MDA/ml during saline plus 50 mg of ACh, p 5 NS).
Discussion
To our knowledge, the present study is the first to show that
the infusion of vitamin C attenuated the constrictor response
of the epicardial spasm coronary arteries to ACh but had no
effect on the response to ACh in control coronary arteries. The
effect of vitamin C is unlikely to be due to the spontaneous
change of the response to the repeated infusion of ACh
because the saline infusion in the same protocol as the vitamin
C infusion otherwise had no effect on the response of the
epicardial diameter in the spasm coronary arteries to ACh.
Also, the effect of vitamin C was not due to the higher basal
tone and the hypercontractile response to ACh of spasm
coronary arteries because the attenuation with vitamin C was
not significantly correlated with the basal coronary diameter,
the dilator response to nitroglycerin and the contractile response
to ACh. Furthermore, the dilator response of spasm coronary
arteries to nitroglycerin, an endothelium-independent relax-
ant, was not affected by vitamin C infusion. Thus, the effect of
vitamin C on the vasomotor reactivity of spasm coronary
arteries in response to ACh may be mediated at least in part by
an improvement in endothelium-dependent vasodilation. The
present study also showed that the beneficial effect of vitamin
C on spasm coronary arteries was associated with a suppres-
sion of the increase in the production of TBARS, a marker of
lipid peroxidation, in the coronary circulation during the ACh
infusion, indicating that the intracoronary infusion of vitamin
C effectively exerted an antioxidant effect on the coronary
circulation. Therefore, the suppression of oxidative stress or
oxygen-derived free radicals in the coronary arteries may
contribute to the vitamin C-induced attenuation of the con-
strictor response to ACh in spasm coronary arteries.
We recently demonstrated (1) that the deficiency or de-
crease in endothelium-derived nitric oxide plays a role in the
mechanisms of the increased basal tone and the supersensitive
constrictor response to ACh in spasm coronary arteries. The
present study shows that the production of TBARS in the
coronary circulation during ACh infusion was significantly
higher in patients with coronary spastic angina than in control
patients, irrespective of the presence or absence of myocardial
ischemia due to coronary spasm. Furthermore, Miwa et al. (19)
recently showed that plasma levels of vitamin E, a natural
antioxidant, were decreased in patients with coronary spastic
angina. These data suggest that oxidative stress may be in-
creased in patients with coronary spastic angina. Therefore, it
is possible that the increase in oxidative stress and oxygen-
derived free radicals may cause endothelial dysfunction or
inactivate endothelium-derived nitric oxide, leading to the
hyperconstrictive response to ACh in spasm coronary arteries
of patients with coronary spastic angina.
Possible sources of increase in oxidative stress. Several
lines of clinical studies from our (7,15) and other (11,20)
laboratories indicate that oxidative stress is increased in ciga-
rette smokers, resulting in the impairment of nitric oxide–
mediated endothelium-dependent vasodilation in vivo in hu-
mans. Furthermore, cigarette smoking is known to be highly
prevalent in patients with coronary spastic angina (21). There-
fore, oxidative stress associated with cigarette smoking may be
one of the free radical sources in patients with coronary spastic
angina and cigarette smoking. However, cigarette smoking
cannot completely explain the abnormal vasomotor reactivity
of spasm coronary arteries because the present study showed
that the vitamin C infusion was also effective in the subgroup
of patients with coronary spastic angina and nonsmoking. The
myocardial ischemia/reperfusion, which is known to generate
oxygen-derived free radicals in coronary endothelium and
myocardium (22,23), is repeated by coronary spasm and is one
of the characteristic features in patients with coronary spastic
angina. Therefore, it could be another source of oxidative
stress in spasm coronary arteries.
TBARS production. It should be noted that the production
of TBARS in the coronary circulation during ACh infusion was
increased in control patients as well as patients with coronary
spastic angina. Intracoronary infusion of ACh is known to
increase coronary blood flow (24,25). Laurindo et al. (26)
previously reported that the increase in blood flow triggers
endothelial free radical generation; such generation of oxygen-
derived free radicals may partly explain the increase in TBARS
in the coronary circulation during ACh infusion, even in
control coronary arteries. In patients with coronary spastic
angina, the preexisting oxidative stress due to smoking, re-
peated myocardial ischemia/reperfusion or other causes may
increase the susceptibility of lipid peroxidation in plasma
lipoproteins and vascular cell membranes to oxygen-derived
free radicals produced in the circulation during the ACh-
induced increase in blood flow because the preexisting oxida-
tive stress could have consumed the antioxidants in plasma and
the intracellular antioxidant defenses of vascular cells in the
spasm coronary arteries. This may partly contribute to the
higher production of TBARS in the coronary circulation in
spasm coronary arteries than in control coronary arteries
during ACh infusion, even at the subthreshold concentrations
that did not induce coronary spasm. The endothelial genera-
tion of oxygen-derived free radicals by the increase in blood
flow during ACh infusion, which possibly also occurs in the
epicardial coronary arteries, may play a critical role in the
abnormal vasomotor reactivity of the spasm coronary arteries
in response to ACh because the infusion of vitamin C alone
had no effect on the baseline diameter of the spasm coronary
arteries.
Study limitations. There are few reports showing direct
evidence of the long-term therapeutic value of the vitamin C
administration in patients with coronary artery disease. It also
remains to be determined whether vitamin C treatment could
prevent anginal attack in patients with coronary spastic angina.
Many assays are available for measuring lipid peroxidation, but
no single assay accurately reflects free radical generation.
TBARS measurement is also susceptible to artifacts caused by
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variations in sample lipid content and iron contamination of
reagents. In the present study, we prevented autooxidation of
the samples by addition of butylated hydroxytoluene to the
samples.
Conclusions. The present results indicate that vitamin C
improves the abnormal vasomotor reactivity in response to
ACh in epicardial coronary arteries of patients with coronary
spastic angina. Oxidative stress or oxygen-derived free radicals
may at least in part play a role in the abnormal vasomotor
reactivity in spasm coronary arteries.
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